title: Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors.
abstract: Suicide gene therapy using the herpes simplex thymidine kinase gene and ganciclovir is an attractive strategy for solid tumors. Early animal studies involved intratumoral injection of retroviral producer cells or unprocessed supernatant to generate an antitumor effect. Xenotransplantation of producer cells proved effective in several models, but the crude supernatants from the same cells were of insufficient titer to produce antitumor effects. We have developed new non-murine producer lines that yield replication-defective retroviral vectors encoding thymidine kinase at high titer which are then further purified and processed, resulting in pharmaceutical grade retroviral vectors with titers of up to 10(8) cfu/ml. Purified, high-titer retroviral preparations were injected directly into solid tumors in two syngeneic mouse tumor models. Significant antitumor responses and some cures were observed following systemic ganciclovir therapy. Assays using monoclonal antibodies to measure thymidine kinase protein expression at the single cell level in vitro and in vivo were developed so that therapeutic transgene expression could be quantified. Intralesional delivery resulted in transduction of over 20% of tumor cells in a protocol designed to maximize transduction on the basis of separate analyses of route, dosage, and schedule of vector administration. A consensus strategy evolved in which the combined effects of increased titer and a longer duration of retroviral vector administration interact to maximize transduction efficiency. These results indicate that purified high-titer retroviral vectors have the potential to transfer effective quantities of therapeutic genes into solid tumors in human subjects and highlight some pharmacologic factors that could be valuable in the design of clinical gene therapy protocols.
authors.affiliation: Cancer Therapeutics Group, Chiron Technologies Center For Gene Therapy, San Diego, CA 92121, USA.
authors.forename: W R
authors.initials: WR
authors.lastname: Smiley
authors.forename: B
authors.initials: B
authors.lastname: Laubert
authors.forename: B D
authors.initials: BD
authors.lastname: Howard
authors.forename: C
authors.initials: C
authors.lastname: Ibañez
authors.forename: T C
authors.initials: TC
authors.lastname: Fong
authors.forename: W S
authors.initials: WS
authors.lastname: Summers
authors.forename: F J
authors.initials: FJ
authors.lastname: Burrows
mesh_terms: D000818:Animals; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics*; D018139:Simplexvirus / Q000235:genetics*; D013937:Thymidine Kinase / Q000235:genetics; D017186:Titrimetry; D014161:Transduction, Genetic
chemical_list: D013937:Thymidine Kinase